| 000 | 01717 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517141234.0 | ||
| 264 | 0 | _c20171221 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1468-1331 | ||
| 024 | 7 |
_a10.1111/ene.13260 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchreglmann, S R | |
| 245 | 0 | 0 |
_aPyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. _h[electronic resource] |
| 260 |
_bEuropean journal of neurology _c04 2017 |
||
| 300 |
_a545-551 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aCholinesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFludrocortisone _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypotension, Orthostatic _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 |
_aPyridostigmine Bromide _xpharmacology |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBüchele, F | |
| 700 | 1 | _aSommerauer, M | |
| 700 | 1 | _aEpprecht, L | |
| 700 | 1 | _aKägi, G | |
| 700 | 1 | _aHägele-Link, S | |
| 700 | 1 | _aGötze, O | |
| 700 | 1 | _aZimmerli, L | |
| 700 | 1 | _aWaldvogel, D | |
| 700 | 1 | _aBaumann, C R | |
| 773 | 0 |
_tEuropean journal of neurology _gvol. 24 _gno. 4 _gp. 545-551 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ene.13260 _zAvailable from publisher's website |
| 999 |
_c26903390 _d26903390 |
||